Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) fundamentals
Aarey Drugs & Pharmaceuticals Limited is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as AAREYDRUGS (ISIN INE198H01019). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Aarey Drugs & Pharmaceuticals Limited does
Aarey Drugs and Pharmaceuticals Limited is an India-based company, which is engaged in the manufacturing and trading of drugs and pharmaceuticals. The Company is in active pharmaceutical ingredients (API)/bulk drug manufacturing and offers a range of products for various industrial applications. Its products include N-Methyl Urea, Mefenamic acid, Doxofylline, Lumefantrine, Nimesulide, Albendazole, Carbamazepine and Oxcarbazepine. The Company's chemical and solvents include Aeromatics Chemical, Chemical acid, Chlor Alkali, Industrial Alchols, Industrial Ketones, Glycols and Glycol Ethers, Fiber Intermediates, Industrial Amines, Acetates and Esters, Industrial Oleochemicals, Industrial Intermediates, Chlorinated Solvents, Industrial Olefines, Industrial Phosphates, Industrial Fertilizers, Industrial Monomers and Industrial Chemicals. Its chemical acid products include Acetic acid, Citric acid, Formic acid and Hydrochloric acid.
Valuation and market data
| Last close | ₹98.71 |
|---|---|
| Market capitalisation | ₹279 crore |
| Enterprise value | ₹281 crore |
| P/E (TTM) | 0.00 |
| Price to book | 2.02 |
| Price to sales (TTM) | 0.66 |
| Book value per share | ₹48.92 |
| Dividend yield | 0.00% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Fri Aug 06 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹478 crore | ₹5 crore | ₹4 crore | 0.00 |
| Mar 2025 | ₹484 crore | ₹6 crore | ₹4 crore | 1.42 |
| Mar 2024 | ₹403 crore | ₹5 crore | ₹5 crore | 1.84 |
| Mar 2023 | ₹422 crore | ₹6 crore | ₹4 crore | 1.49 |
| Mar 2022 | ₹495 crore | ₹10 crore | ₹7 crore | 2.72 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 37.7% |
|---|---|
| Foreign institutions (FII) | 4.8% |
| Mutual funds | 0.0% |
| Other domestic institutions | 1.6% |
| Retail and others | 55.9% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.